Sally Church on the Pharma Strategy Blog analyzes the significance of new research that has identified a new oncogene associated with 1 in 12 breast cancers.
Research published by Holland et al, in the journal, EMBO Molecular Medicine, has identified the ZNF703 oncogene to be linked with Luminal B breast cancer.
This is the first oncogene to be discovered in 5 years since HER2, and has tremendous potential as a target for drug development.
As Sally comments on her blog “it’s much easier to design a drug or therapeutic once you have a valid target to aim for and with more specific targeting, comes improved patient outcomes.”
This is important news and Sally’s blog post has more in-depth insight and analysis.